ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1636

Age-associated B Cells Contribute to Inflammation of Takayasu’s Arteritis in an Antibody-secreting Cell Differentiation Independent Manner

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1063

AI –Driven Precision in Rheumatologic Emergencies: Unveiling the Capability of Top Healthcare Chatbots

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 1420

Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1214

All-Cause Mortality in Patients with Chronic Musculoskeletal Pain Using Pregabalin or Duloxetine: A Retrospective Cohort Study in US Veterans

Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1269

Altered Tryptophan Metabolism in Juvenile Dermatomyositis Is Associated with Muscle Damage and Mental Health

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 0980

Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 0942

An Aged K/BxA Arthritis Mouse Model Develops Features of Interstitial Lung Disease with Pulmonary Fibrosis and Bronchus-Associated T-Cell Aggregates Without a Pulmonary Insult, and Correlates with Worsening Arthritis Scores

Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 1286

An Analysis of Diversity, Equity, and Inclusion Initiatives in US ACGME-accredited Adult Rheumatology Fellowship Programs

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1029

An Analysis of Osteoporosis Screening in Males vs. Females Across Lehigh Valley Health Network

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1211

An Evaluation of the Efficacy, Pharmacokinetics and Safety, of the Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist RTX-GRT7039 – a Placebo-controlled Study in Patients with Osteoarthritis Knee Pain

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1273

An Investigation of Traumatic Events and Mental Health in cSLE

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1423

An Observational Analytical Study on HCV Patients with Sicca Manifestations Before and After Direct-Acting Antivirals in Comparison with Sjogren’s Disease; Infection versus Autoimmunity

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1348

Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1621

Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1018

Analysis of Medication Usage and Monthly Costs in Hospitalized Patients with Rheumatic Diseases: A Retrospective Observational Study

Healthcare Disparities in Rheumatology Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].